FGF21 and metabolic dysfunction-associated steatohepatitis: The ENLIVEN (Pegozafermin, fibroblast growth factor 21 (FGF21) analog) [18] and SEMA-NASH (Semeglutide) [19] trials outrightly exclude patients with BMI < 25 kg/m2, while other trials, such as MASTERO NASH (Resmetirom, thyroid hormone receptor-β agonist) [20], HARMONY (Efruxifermin, FGF21 analog) [21], FALCON (Pegbelfermin, FGF21 analog) [22], and FLINT (Obeticholic Acid, Farsenoid X nuclear receptor ligand) [23], have an average BMI > 35 kg/m2 across treatment and control groups, suggesting predominantly overweight/obese participants.